

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Weshington, D.C. 20231 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/858,198	05/14/2001	Rudolf H. Aebersold	P-IS 4693	2506
	23601 7:	590 08/16/2002			
CAMPBELL & FLORES LLP 4370 LA JOLLA VILLAGE DRIVE 7TH FLOOR				EXAMINER	
				CEPERLEY, MARY	
	SAN DIEGO, CA 92122			ART UNIT	PAPER NUMBER
				1641	
				DATE MAILED: 08/16/2002	9

Please find below and/or attached an Office communication concerning this application or proceeding.

			Appl	ication N .	Applicant(s)		
			09/8	58,198	AEBERSOLD ET AL.		
	Offic	Action Summary	Exam	nin r	Art Unit		
				(Molly) E. Ceperley	1641		
Period f		ING DATE of this communic	ation appears o	n the cover sheet with th	c rrespondence ac	ldress	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status	_						
1)	•	ve to communication(s) file					
2a)□			b)⊡ This actio				
3)	closed in	s application is in condition accordance with the praction				ne merits is	
•	ion of Clair		onnlination				
•		1-105 is/are pending in the		m consideration			
	•	above claim(s) is/are	williawii iioi	n consideration.			
		is/are allowed.					
		is/are rejected.					
· · · · · · · · · · · · · · · · · · ·		is/are objected to.	nn andlar alaati	t			
•	ion Papers	<u>-105</u> are subject to restriction	on and/or election	on requirement.			
	•	cation is objected to by the	Examiner.				
•	•	g(s) filed on is/are: a		b) objected to by the Exa	aminer.		
, ,		may not request that any obje	•				
11)		ed drawing correction filed					
	If approve	d, corrected drawings are requ	uired in reply to th	nis Office action.			
12)	The oath or	declaration is objected to t	by the Examine	r			
Pri rity u	ınder 35 U	.S.C. §§ 119 and 120					
13)[Acknowled	dgment is made of a claim f	or foreign priori	ty under 35 U.S.C. § 119(a)-(d) or (f).		
a)[a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Cert	tified copies of the priority d	ocuments have	been received.			
	2. Cert	tified copies of the priority d	ocuments have	been received in Applica	tion No		
* 0	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
	* See the attached detailed Office action for a list of the certified copies not received. 4) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
а	a) The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)							
2) Notic	e of Draftsper	es Cited (PTO-892) son's Patent Drawing Review (PT sure Statement(s) (PTO-1449) Pap			Patent Application (PT		

Notice to Comply

Application No. Applicant(s) 091858198 Achersoldet al Art Unit Examiner 1641 Ceperley

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice
is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the
provisions of 37 CFR 1.136(a)).

the	e nucleotide and/or amino acid sequence disclosure contained in this application does not comply with requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
Ø	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
Þ(3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Application/Control Number: 09/858,198

Art Unit: 1641

1) Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. ** Claims 1-75, drawn to methods of labeling a molecule and analyzing a molecule, classified in class 530.

Page 2

II. ** Claims 76-105, drawn to solid support-based compositions, classified in class 436.

**Note: Each of Inventions I and II is drawn to multiple patentably distinct inventions, each invention being defined by the specific type of "chemical group". Each separate and distinct invention is defined as the combination of a specific "cleavable functional group", a specific "functional group" AND a specific "reactive group" AND a defined structure which indicates how these three variables are positioned relative to each other (i.e. these specifics constitute a distinct "chemical group"). Upon election of either of Inventions I or II, applicants are required to further elect a single combination of the variables defined above to define a "chemical group"; this election will determine the specific invention (not an election of species) which is to be examined. The claims will then be examined on the merits to the extent that they encompass the elected invention. The methods of use or compositions per se (based on the election of either Invention I or Invention II) will further be examined to the extent that they encompass species which are not patentably distinct from the elected "chemical group".

- 2) The inventions are distinct, each from the other because of the following reasons:
- a) Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the method of Invention I does not require the use of a "solid support" as defined in claim 76 which requires a "tag" and a specific spatial arrangement of the "cleavable functional group", "tag", and

Application/Control Number: 09/858,198

Art Unit: 1641

"reactive group covalently linked to a sample molecule". Further, the composition of Invention II would not be useful in the method of Invention I since the method of Invention I requires that the sample be contacted with a solid support while the composition of Invention II already has the sample covalently linked to the reactive group.

- that different types of "cleavable functional groups", "functional groups" and "reactive groups" provide different modes of operation. For example, a photo-cleavable group and an enzyme-cleavable group would be expected to be very different from each other in terms of chemical structure and how they function. Similarly, a reactive hydrazide group is very different in structure and function from a reactive thiol group.
- 3) Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter requiring divergent fields of search and divergent patentability considerations, restriction for examination purposes as indicated is proper.
- 4) Applicants are advised that the reply to this requirement to be complete must include an election of the invention (see the "**Note" above) to be examined even though the requirement be traversed (37 CFR 1.143).
- *5)* Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/858,198

Art Unit: 1641

Applicants are advised that in accordance with the court decisions in *In re Ochiai*, {71
 F.3d 1565, 37 USPQ2d 1127 (Fed. Cir. 1995)} and *In re Brouwer* {77 F.3d 422, 37 USPQ2d 1663 (Fed. Cir. 1996)}, in the event that a product claim is found to be allowable, a method of use claim *which is*

of the same scope as the allowed product claim may be rejoined with the allowed product claim.

7) Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. (Molly) Ceperley whose telephone number is (703) 308-4239. The examiner can normally be reached from 8 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,
Long Le, can be reached at (703) 305-3399. The fax phone number for responses to be filed BEFORE
final rejection is (703) 872-9306. The fax phone number for responses to be filed AFTER final rejection is
(703) 872-9307.

Questions which are <u>NOT RELATED TO THE EXAMINATION ON THE MERITS</u>, should be directed to <u>TC 1600 CUSTOMER SERVICE</u> at (703) 308-0198. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

August 15, 2002

Mary E. Ceperley
Mary E. (Molly) Ceperley

Primary Examiner Art Unit 1641